Bioinformatics-Based Identification of HDAC Inhibitors as Potential Drugs to Target EGFR Wild-Type Non-Small-Cell Lung Cancer

Patients with EGFR-mutant non-small-cell lung cancer (NSCLC) greatly benefit from EGFR-tyrosine kinase inhibitors (EGFR-TKIs) while the prognosis of patients who lack EGFR-sensitive mutations (EGFR wild type, EGFR-WT) remains poor due to a lack of effective therapeutic strategies. There is an urgent...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yizhe, Zheng, Chunlei, Lu, Wenqing, Wang, Duo, Cheng, Yang, Chen, Yang, Hou, Kezuo, Qi, Jianfei, Liu, Yunpeng, Che, Xiaofang, Hu, Xuejun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982742/
https://www.ncbi.nlm.nih.gov/pubmed/33763356
http://dx.doi.org/10.3389/fonc.2021.620154

Ejemplares similares

Ejemplares similares